RBC Capital lowered the firm’s price target on Moderna (MRNA) to $62 from $75 and keeps a Sector Perform rating on the shares following a COVID vaccine sale beat that was primarily driven by an ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...